سعر روتا دانسيترون 8مجم4 مل 5 امبول وريد .عضل 2025

Ondansetron 8 mg/4 ml injection for IM/IV use or infusion, 5 ampoules; Rotabiogen, Egypt.

• Prevention of nausea and vomiting with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.Population: Adults and children 6 months and olderDailyMed (U.S. National Library of Medicine)
• Prevention of postoperative nausea and/or vomiting.Population: Adults and children 1 month and olderDailyMed (U.S. National Library of Medicine)

• CINV (adults, >=7%): diarrhoea, headache, fever. PONV (adults, >=10%): headache; children 1-24 months: diarrhoea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity (e.g. anaphylaxis) to the product or its components; concomitant apomorphine (profound hypotension and loss of consciousness).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Dose-dependent QT prolongation and torsade de pointes; avoid in congenital long QT syndrome; correct hypokalaemia/hypomagnesaemia; ECG monitoring in at-risk patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome (especially with serotonergic drugs); myocardial ischaemia (do not exceed recommended infusion rate); may mask progressive ileus/gastric distension; hypersensitivity incl. cross-reactivity with other 5-HT3 antagonists.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• ApomorphineContraindicated: profound hypotension and loss of consciousness reported.DailyMed (U.S. National Library of Medicine)
• Serotonergic drugs (SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue)Risk of serotonin syndrome; monitor and discontinue if symptoms occur.DailyMed (U.S. National Library of Medicine)
• Potent CYP3A4 inducers (phenytoin, carbamazepine, rifampin)Increase ondansetron clearance and lower blood levels; no dose adjustment recommended.DailyMed (U.S. National Library of Medicine)

• Epidemiological studies on major birth defects show inconsistent findings with methodological limitations; postmarketing data have not identified miscarriage or adverse maternal outcome risk; animal studies showed no fetal harm.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Present at low levels in milk (relative infant dose 3.7%) after IV doses up to 4 mg/day; unlikely to cause clinically relevant infant exposure; no adverse infant effects reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ondansetron: Selective 5-HT3 receptor antagonist; not a dopamine-receptor antagonist (US label).